S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)

Aldeyra Therapeutics - ALDX Stock Forecast, Price & News

$7.47
+0.48 (+6.87%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.15
$7.60
50-Day Range
$3.17
$7.74
52-Week Range
$2.36
$9.81
Volume
629,392 shs
Average Volume
1.00 million shs
Market Capitalization
$435.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Aldeyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
154.4% Upside
$19.00 Price Target
Short Interest
Healthy
5.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.54mentions of Aldeyra Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$2.80 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.35) to ($1.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

151st out of 1,135 stocks

Pharmaceutical Preparations Industry

63rd out of 557 stocks

ALDX stock logo

About Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aldeyra Therapeutics Stock Up 6.9 %

ALDX traded up $0.48 during trading on Friday, reaching $7.47. The stock had a trading volume of 629,392 shares, compared to its average volume of 1,003,828. Aldeyra Therapeutics has a one year low of $2.36 and a one year high of $9.81. The company has a market capitalization of $435.65 million, a price-to-earnings ratio of -6.61 and a beta of 1.43. The company has a current ratio of 12.36, a quick ratio of 13.60 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average is $4.67 and its two-hundred day moving average is $4.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Oppenheimer lifted their price objective on Aldeyra Therapeutics to $11.00 in a research report on Thursday, June 9th. Citigroup lifted their price target on shares of Aldeyra Therapeutics from $21.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, June 9th. Berenberg Bank started coverage on shares of Aldeyra Therapeutics in a report on Tuesday, May 24th. They issued a "buy" rating and a $28.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, August 10th. The stock was bought at an average cost of $7.85 per share, with a total value of $117,750.00. Following the transaction, the insider now directly owns 11,350,085 shares in the company, valued at approximately $89,098,167.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Todd C. Brady purchased 17,700 shares of Aldeyra Therapeutics stock in a transaction dated Thursday, June 23rd. The stock was purchased at an average cost of $3.36 per share, for a total transaction of $59,472.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,216,535 shares of the company's stock, valued at $4,087,557.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Perceptive Advisors Llc purchased 15,000 shares of the company's stock in a transaction that occurred on Wednesday, August 10th. The stock was purchased at an average price of $7.85 per share, for a total transaction of $117,750.00. Following the purchase, the insider now owns 11,350,085 shares in the company, valued at $89,098,167.25. The disclosure for this purchase can be found here. Insiders have acquired 497,600 shares of company stock valued at $2,803,640 in the last three months. 6.90% of the stock is currently owned by company insiders.

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

Why Aldeyra Therapeutics' Shares Are Soaring Today?
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Company Calendar

Last Earnings
10/27/2021
Today
8/13/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+124.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-57,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.98 per share

Miscellaneous

Free Float
54,299,000
Market Cap
$435.65 million
Optionable
Optionable
Beta
1.43














ALDX Stock - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price forecast for 2022?

4 analysts have issued 1 year target prices for Aldeyra Therapeutics' shares. Their ALDX share price forecasts range from $11.00 to $28.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 154.4% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2022?

Aldeyra Therapeutics' stock was trading at $4.00 at the beginning of 2022. Since then, ALDX shares have increased by 86.8% and is now trading at $7.47.
View the best growth stocks for 2022 here
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.01. During the same quarter in the previous year, the business earned ($0.23) earnings per share.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Prosight Management LP (3.40%), Eagle Asset Management Inc. (2.58%), UBS Group AG (1.30%), FMR LLC (1.16%), Assenagon Asset Management S.A. (1.11%) and Renaissance Technologies LLC (0.88%). Insiders that own company stock include Ben Bronstein, David Mcmullin, Joshua Reed, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $7.47.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $435.65 million. The biotechnology company earns $-57,780,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630.

This page (NASDAQ:ALDX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.